Kilitch Drugs (I) Ltd.

BSE: KILITCH524500ISIN INE729D01010

Healthcare
Pharmaceuticals
BSE Healthcare

Share price

₹208.85+5.95 (+2.93%)

as of 4 Nov 2026

Prices adjusted for splits and bonuses; cash dividends excluded. Volume shows actual shares traded. Earlier history is omitted pending corporate-action verification.

Splits and bonuses

24 Mar 2026 · Bonus 1:1

52W high: ₹267.90
52W low: ₹121.10
Off 52W high: -22.04%
1M return: -10.56%
3M return: +7.68%
6M return: +34.87%
1Y return: +6.80%
20D avg volume: 4,735
50 DMA: ₹205.09
200 DMA: ₹177.52

Key ratios Consolidated

Market cap: ₹730.17 Cr
Current price: ₹208.85
52W high / low: ₹267.90 / ₹121.10
Face value: ₹10.00
P/E: 25.00
P/B: 2.61
EPS (TTM): ₹8.35
Book value / share: ₹79.99
ROE: —
ROCE: 13.20%
Operating margin: —
Net margin: —
Debt / equity: 0.32
Net debt: ₹72.94 Cr
Interest cover: 7.95
Dividend yield: —
Dividend / share (TTM): —
Payout: —
Cash conversion cycle: 80.7 days

Financials

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24	Q2 FY24
Income statement
	44.88	89.60	53.81	48.92	43.14	61.23	56.17	47.48	33.45	44.82	31.80	41.20
	2.90	0.49	1.53	6.66	2.56	1.70	1.73	5.16	2.57	0.47	2.96	0.49
	47.78	90.10	55.34	55.59	45.70	62.92	57.89	52.64	36.02	45.29	34.75	41.69
	43.91	69.89	49.74	46.19	42.25	49.08	49.64	42.29	34.38	39.99	31.93	34.91
	23.92	42.69	32.60	24.29	26.22	30.15	32.54	24.43	18.64	25.09	16.72	20.56
	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—	—	—	—
	4.14	4.29	3.51	3.76	2.75	2.88	3.14	2.59	2.71	2.37	2.51	2.61
	0.88	1.44	1.15	1.44	1.53	1.60	1.40	0.31	1.73	1.32	1.60	1.51
	1.09	0.98	0.94	0.86	0.84	0.85	0.81	0.60	0.85	0.93	0.81	0.82
	14.09	19.02	13.26	13.76	11.66	15.05	7.37	8.59	6.81	5.00	7.06	7.08
	3.86	20.21	5.60	9.40	3.45	13.84	8.25	10.35	1.65	5.30	2.82	6.78
	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	3.86	20.21	5.60	9.40	3.45	13.84	8.25	10.35	1.65	5.30	2.82	6.78
	1.90	5.33	1.28	1.36	1.19	3.63	2.64	1.74	1.54	1.62	1.08	1.69
	1.97	14.88	4.32	8.04	2.26	10.22	5.62	8.61	0.11	3.68	1.74	5.09
	0.83	4.24	2.50	4.97	1.88	6.47	3.71	5.36	0.83	2.24	1.85	2.93
Key metrics
	5.83	22.63	7.69	11.70	5.82	16.29	10.46	11.26	4.23	7.55	5.23	9.11
	13.00%	25.30%	14.30%	23.90%	13.50%	26.60%	18.60%	23.70%	12.60%	16.80%	16.40%	22.10%
	4.40%	16.60%	8.00%	16.40%	5.20%	16.70%	10.00%	18.10%	0.30%	8.20%	5.50%	12.40%
	—	6.40%	—	3.40%	—	6.80%	—	—	—	—	—	—
	4.00%	46.30%	-4.20%	3.00%	29.00%	36.60%	76.60%	15.20%	—	—	—	—
	-12.80%	45.60%	-23.10%	-6.60%	1,954.50%	177.70%	223.00%	69.20%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22
Income statement
	237.21	235.47	198.32	154.37	139.60	114.23
	11.58	11.24	11.16	4.48	2.92	2.91
	248.81	246.71	209.48	158.85	142.52	117.14
	209.73	208.06	175.00	139.50	130.50	107.53
	123.50	125.07	105.75	79.08	74.53	65.48
	0.00	0.00	0.00	—	—	—
	15.70	14.31	11.32	10.01	11.73	6.18
	4.91	5.56	5.04	5.93	4.92	1.20
	3.87	3.62	3.11	3.35	3.55	2.47
	60.13	58.44	50.95	27.29	24.12	26.77
	39.07	38.65	34.47	19.36	12.01	9.61
	0.00	0.00	0.00	0.00	0.00	0.00
	39.07	38.65	34.47	19.36	12.01	9.61
	9.87	9.15	9.53	5.78	3.73	3.40
	29.21	29.50	24.94	13.57	8.28	6.21
	12.54	8.91	16.60	9.17	6.71	4.73
Key metrics
	47.85	47.83	42.62	28.64	20.48	13.28
	20.17%	20.30%	21.50%	18.60%	14.70%	11.60%
	12.31%	12.50%	12.60%	8.80%	5.90%	5.40%
	—	13.20%	17.30%	—	—	—
	14.03%	18.70%	28.50%	10.60%	22.20%	—
	9.36%	18.30%	83.80%	63.90%	33.30%	—
	—	-75.55	17.54	—	—	—
	—	0.81	0.70	—	—	—
	—	0.32	0.25	—	—	—
	—	72.94	39.62	—	—	—
	—	80.7	84.5	—	—	—
Balance sheet
	—	457.75	312.78	—	—	—
	—	222.20	173.92	—	—	—
	—	15.77	9.80	—	—	—
	—	120.18	84.74	—	—	—
	—	11.52	15.31	—	—	—
	—	21.73	14.47	—	—	—
	—	48.70	45.52	—	—	—
	—	79.65	54.16	—	—	—
	—	121.60	84.31	—	—	—
	—	88.71	49.42	—	—	—
	—	30.11	21.65	—	—	—
	—	58.60	27.77	—	—	—
	—	276.87	200.46	—	—	—
Cash flow
	—	23.96	17.54	—	—	—
	—	-100.44	-39.95	—	—	—
	—	82.45	13.24	—	—	—
	—	99.51	0.00	—	—	—

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24	Q2 FY24
Income statement
	40.91	71.97	44.67	37.81	34.12	56.30	46.51	45.35	33.42	39.14	29.77	31.57
	3.55	1.14	1.61	7.61	3.50	2.33	2.37	5.81	3.21	0.90	3.40	0.92
	44.46	73.11	46.28	45.42	37.62	58.63	48.88	51.16	36.63	40.03	33.16	32.49
	37.51	53.78	40.11	35.35	31.64	43.63	39.36	40.58	31.04	34.77	26.58	26.56
	20.25	28.53	25.32	15.68	18.27	27.13	24.50	22.95	18.62	22.41	14.91	15.34
	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—	—	—	—
	3.52	3.61	3.04	3.28	2.40	2.58	2.73	2.49	2.22	1.91	2.03	2.00
	0.49	0.58	0.60	0.68	0.59	0.72	0.49	0.42	0.49	0.44	0.53	0.42
	0.76	0.70	0.56	0.53	0.50	0.51	0.47	0.40	0.35	0.41	0.30	0.28
	12.69	18.88	12.29	13.11	10.65	14.14	6.78	8.54	5.73	4.32	5.57	6.18
	6.95	19.33	6.17	10.07	5.98	15.00	9.52	10.58	5.59	5.26	6.58	5.93
	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—	—	—	—
	6.95	19.33	6.17	10.07	5.98	15.00	9.52	10.58	5.59	5.26	6.58	5.93
	1.90	5.33	1.28	1.36	1.19	3.62	2.64	1.74	1.54	1.62	1.08	1.69
	5.05	14.00	4.89	8.72	4.79	11.37	6.88	8.85	4.05	3.64	5.50	4.24
	1.45	4.08	2.74	5.27	2.98	7.07	4.28	5.50	2.52	2.26	3.48	2.60
Key metrics
	8.20	20.61	7.33	11.28	7.07	16.23	10.48	11.40	6.43	6.11	7.41	6.63
	20.00%	28.60%	16.40%	29.80%	20.70%	28.80%	22.50%	25.10%	19.20%	15.60%	24.90%	21.00%
	12.30%	19.50%	10.90%	23.10%	14.00%	20.20%	14.80%	19.50%	12.10%	9.30%	18.50%	13.40%
	—	5.10%	—	2.90%	—	5.60%	—	—	—	—	—	—
	19.90%	27.80%	-4.00%	-16.60%	2.10%	43.80%	56.20%	43.60%	—	—	—	—
	5.40%	23.10%	-28.90%	-1.50%	18.30%	212.40%	25.10%	108.70%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22
Income statement
	195.36	188.57	181.59	131.60	117.78	105.16
	13.91	13.85	13.72	6.19	4.60	4.56
	209.27	202.42	195.30	137.79	122.38	109.72
	166.75	160.87	154.61	114.43	102.93	95.79
	89.78	87.80	93.19	66.33	58.27	60.29
	0.00	0.00	0.00	—	—	—
	13.45	12.34	10.03	7.91	7.47	6.15
	2.35	2.44	2.13	1.91	0.99	0.66
	2.55	2.29	1.74	1.24	1.34	0.96
	56.97	54.93	48.70	23.23	23.35	22.34
	42.52	41.55	40.69	23.35	19.45	13.93
	0.00	0.00	0.00	—	—	—
	42.52	41.55	40.69	23.35	19.45	13.93
	9.87	9.15	9.53	5.78	3.73	3.40
	32.66	32.40	31.16	17.57	15.72	10.53
	13.54	9.57	19.37	11.03	10.09	6.76
Key metrics
	47.42	46.28	44.56	26.50	21.78	15.55
	24.27%	24.50%	24.50%	20.10%	18.50%	14.80%
	16.72%	17.20%	17.20%	13.40%	13.30%	10.00%
	—	11.20%	15.20%	—	—	—
	7.18%	3.80%	38.00%	11.70%	12.00%	—
	2.41%	4.00%	77.30%	11.80%	49.30%	—
	—	-82.72	-31.64	—	—	—
	—	0.38	0.49	—	—	—
	—	0.27	0.19	—	—	—
	—	79.08	41.68	—	—	—
	—	117.2	103.1	—	—	—
Balance sheet
	—	499.46	358.16	—	—	—
	—	206.14	162.38	—	—	—
	—	9.30	7.41	—	—	—
	—	117.24	83.40	—	—	—
	—	11.52	15.31	—	—	—
	—	15.08	6.66	—	—	—
	—	19.27	19.16	—	—	—
	—	68.19	47.42	—	—	—
	—	107.17	77.20	—	—	—
	—	88.38	49.09	—	—	—
	—	29.78	21.32	—	—	—
	—	58.60	27.77	—	—	—
	—	333.01	252.94	—	—	—
Cash flow
	—	12.32	15.23	—	—	—
	—	-96.00	-41.42	—	—	—
	—	85.57	15.65	—	—	—
	—	95.04	46.87	—	—	—

Compounded growth

Standalone

Sales CAGR 3Y: +16.99%
Sales CAGR 5Y: —
Profit CAGR 3Y: +27.26%
Profit CAGR 5Y: —
Sales YoY (TTM): +7.18%
Profit YoY (TTM): +2.41%

Consolidated

Sales CAGR 3Y: +19.04%
Sales CAGR 5Y: —
Profit CAGR 3Y: +52.73%
Profit CAGR 5Y: —
Sales YoY (TTM): +14.03%
Profit YoY (TTM): +9.36%

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Sep 2026

Promoter holding: 63.77%

Holder	Type	Holding	Previous	Change
KILITCH COMPANY (PHARMA) LIMITED	Promoter	37.92%	—	—
Bhavin Mukund Mehta	Promoter Group	14.43%	—	—
Mukund Mehta	Promoter	6.61%	—	—
Mira Bhavin Mehta	Promoter Group	4.81%	—	—
DIPAK KANAYALAL SHAH	Public	3.15%	—	—
INVESTOR EDUCATION AND PROTECTION FUND AUTHORITY MINISTRY OF CORPORATE AFFAIRS	Public	2.29%	—	—
MUKUL MAHAVIR AGRAWAL	Public	1.34%	—	—
PREMILABEN RAMESHCHANDRA SHAH	Public	1.14%	—	—

Public shareholders are disclosed individually only above 1%.

Peer comparison

Company	Mkt cap (₹ Cr)	Price (₹)	P/E	ROCE	Sales YoY	Profit YoY	1Y return
Sun Pharmaceutical Industries Ltd.	4,26,112	1,776.00	38.78	17.90%	+12.13% TTM	+4.79% TTM	+4.92%
Divi's Laboratories Ltd.	2,66,424	10,036.00	91.09	19.00%	+16.35% TTM	+26.84% TTM	+47.61%
Torrent Pharmaceuticals Ltd.	1,79,908	4,730.00	85.71	9.10%	+42.06% TTM	-1.92% TTM	+32.24%
Laurus Labs Limited	1,24,601	2,306.10	93.53	19.70%	+23.03% TTM	+95.38% TTM	+134.59%
Zydus Lifesciences Limited	1,18,703	1,190.00	25.85	19.20%	+21.11% TTM	-2.51% TTM	+22.32%
Dr. Reddy's Laboratories Ltd.	1,14,513	1,372.00	41.50	13.90%	-3.53% TTM	-51.90% TTM	+14.26%
Cipla Ltd.	1,13,110	1,400.10	39.63	14.90%	-0.74% TTM	-47.48% TTM	-6.88%
Mankind Pharma Limited	1,04,631	2,533.15	46.22	13.70%	+13.27% TTM	+27.60% TTM	+6.91%
Aurobindo Pharma Ltd.	97,878	1,701.10	26.38	13.60%	+9.09% TTM	+9.48% TTM	+47.79%
Lupin Ltd	92,145	2,015.00	17.65	28.40%	+24.22% TTM	+20.10% TTM	+0.84%
Glenmark Pharmaceuticals ltd	70,608	2,501.85	39.27	16.20%	+32.94% TTM	+138.48% TTM	+35.48%
Alkem Laboratories Limited	62,054	5,190.00	28.15	18.80%	+13.36% TTM	-5.52% TTM	-8.38%
Abbott India Ltd. S	57,685	27,146.85	35.73	41.90%	+6.29% TTM	+11.18% TTM	-7.56%
Biocon Ltd.	56,061	344.00	134.63	2.90%	+5.70% TTM	-55.37% TTM	-9.53%
Gland Pharma Limited	52,105	3,157.70	46.16	13.70%	+17.57% TTM	+46.55% TTM	+65.09%
Ipca Laboratories Ltd.	50,051	1,973.15	36.40	16.40%	+10.59% TTM	+67.91% TTM	+52.33%
GlaxoSmithkline Pharmaceuticals Ltd.	42,904	2,532.60	37.42	55.40%	+12.12% TTM	+20.03% TTM	-4.84%
Ajanta Pharma Ltd.	41,406	3,313.55	32.79	29.40%	+25.01% TTM	+29.70% TTM	+26.89%
Emcure Pharmaceuticals Limited	41,254	2,174.55	37.75	25.10%	+21.12% TTM	+33.34% TTM	+64.07%
J.B. Chemicals & Pharmaceuticals Lt	38,731	2,412.25	47.77	21.90%	+5.87% TTM	+7.56% TTM	+45.79%
Sai Life Sciences Limited	32,855	1,546.30	90.80	18.10%	—	—	+67.49%
PIRAMAL PHARMA LIMITED	31,659	237.80	-151.21	0.80%	+9.43% TTM	-781.93% TTM	+18.60%
ACUTAAS CHEMICALS LIMITED	30,928	3,777.65	70.51	27.70%	+45.18% TTM	+95.78% TTM	+106.30%
Wockhardt Ltd	30,869	1,899.80	76.22	6.40%	+25.70% TTM	+894.12% TTM	+39.18%
RUBICON RESEARCH LIMITED	28,416	1,716.55	98.59	24.30%	—	—	+164.06%
Kilitch Drugs (I) Ltd.	730	208.85	25.00	13.20%	+14.03% TTM	+9.36% TTM	+6.80%

Filings & corporate actions

Recent announcements

Kilitch Drugs India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/11/2026 ,inter alia, to consider and approve unaudited standalone and ....2 Nov 2026 · Board Meeting / Board Meeting
We are hereby submitting the copy of the newspaper publication for information26 Oct 2026 · Company Update / Newspaper Publication
We are hereby submitting the Notice of EGM23 Oct 2026 · AGM/EGM / EGM
We are enclosing herewith the press release23 Oct 2026 · Company Update / Press Release / Media Release
Disvestment of entire stake in Material subsidiary Convert outstanding debt extended to Material subsidiary into equity shares Appointment of Additional independent non-executive director22 Oct 2026 · Others / Outcome without intimation
We hereby inform you that Mr. Venkita Subramanian Rajan has tendered his resignation from the position of Non-executive Independent Director of the Company with immediate effect21 Oct 2026 · Company Update / Resignation of Director
We are submitting herewith the certificate under regulation 74(5) of SEBI DP regulations8 Oct 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
We are submitting herewith the intimation of closure of trading window28 Sep 2026 · Insider Trading / SAST / Closure of Trading Window
We are submitting herewith the scrutinizer''s report for the voting process of 34th Annual General Meeting of Kilitch Drugs India Limited27 Aug 2026 · AGM/EGM / AGM
We are submitting herewith the proceeding of 34th Annual General Meeting27 Aug 2026 · AGM/EGM / AGM
We are submitting herewith the monitoring agency report18 Aug 2026 · Company Update / Monitoring Agency Report
We are submitting herewith the publication of extract of the financial results for the quarter ended 30th June 202618 Aug 2026 · Company Update / Newspaper Publication
Submission of financial results for the quarter ended 30th June 202613 Aug 2026 · Board Meeting / Outcome of Board Meeting
We are submitting herewith the financial results for the quarter ended 30th June 202613 Aug 2026 · Result / Financial Results
Kilitch Drugs India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2026 ,inter alia, to consider and approve unaudited standalone and ....10 Aug 2026 · Board Meeting / Board Meeting
We are submitting herewith the copy of the newspaper publication of extract of AGM Notice4 Aug 2026 · Company Update / Newspaper Publication
We are submitting the copy of Physical intimation made to the shareholders whose email address was not registered1 Aug 2026 · Company Update / General
We are submitting the intimation of Book Closure1 Aug 2026 · Company Update / General
We are submitting herewith the annual report for the FY 2025-261 Aug 2026 · Others / Reg. 34 (1) Annual Report
We are hereby submitting the notice of Annual General Meeting schedule to be held on Thursday, 27th August, 20261 Aug 2026 · AGM/EGM / AGM
Outcome of board meeting is enclosed for ready reference28 Jul 2026 · Others / Outcome without intimation
We are submitting herewith the certification under regulation 74(5) of SEBI (DP) Regulations8 Jul 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
We are submitting herewith the intimation of Closure of window26 Jun 2026 · Insider Trading / SAST / Closure of Trading Window
We are pleased to inform you that we have commenced the Nutraceutical Manufacturing Block of our new plant located at 24/2/1/1 Maldev, Pen, Raigad, Maharashtra India today. i.e 17th June, 202617 Jun 2026 · Company Update / General
We are hereby submitting annual secretarial compliance report for the year ended 31st March, 202627 May 2026 · Company Update / Reg.24(A)-Annual Secretarial Compliance
We are submitting hereby copy of newspaper publication of the extract of financial results for the quarter ended 31st March, 202618 May 2026 · Company Update / Newspaper Publication
We are hereby submitting audited standalone and consolidated financial results of the Company for the quarter ended 31st March, 202615 May 2026 · Board Meeting / Outcome of Board Meeting
We are hereby submitting audited standalone and consolidated financial results for the quarter ended 31st March, 202615 May 2026 · Result / Financial Results
We are hereby submitting the monitoring agency report for the quarter ended 31st March, 202615 May 2026 · Company Update / Monitoring Agency Report
Kilitch Drugs India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 15/05/2026 ,inter alia, to consider and approve the audited financial results ....7 May 2026 · Board Meeting / Board Meeting
We are hereby submitting certificate under regulation 74(5) of SEBI (DP) Regulations received from MUFG Intime India Private Limited, RTA of the Company14 Apr 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Board approved the allotment of bonus equity shares in the ratio of 1:125 Mar 2026 · Others / Outcome without intimation
Closure of Trading Window25 Mar 2026 · Insider Trading / SAST / Closure of Trading Window
We hereby inform you that the Company has fixed Tuesday, 24th March, 2026 as record date in order to determine the number of shareholders entitled for bonus equity shares in the ratio of 1:117 Mar 2026 · Corp. Action / Record Date
We are submitting herewith the Scrutinizer''s Report13 Mar 2026 · AGM/EGM / EGM
We hereby submit proceeding of EGM13 Mar 2026 · AGM/EGM / EGM
We are submitting herewith the copy of paper publication of EGM Notice18 Feb 2026 · Company Update / Newspaper Publication
We are submitting herewith the notice of EGM to be held on 13th March, 202616 Feb 2026 · AGM/EGM / EGM
We are submitting herewith the copy of monitoring agency report for the quarter ended 31st December, 202513 Feb 2026 · Company Update / Monitoring Agency Report
Submitting herewith the newspaper publication of extract of financial results for the quarter ended 31st December, 202513 Feb 2026 · Company Update / Newspaper Publication

Corporate actions

Purpose	Ex date	Record date	Payment date
Bonus issue 1:1	24 Mar 2026	24 Mar 2026	—
Right Issue of Equity Shares	15 Jul 2025	15 Jul 2025	—

Board meetings

6 Nov 2026 Board Meeting - Financial Results
13 Aug 2026 Board Meeting - Financial Results